No abstract

No abstract

No abstract

This work aimed to produce poly(methyl methacrylate) nanoparticles for use in drug encapsulation. The polymer nanoparticles were produced using miniemulsion polymerization technique. Monomer miniemulsion showed moderate stability and polymer average particle size was about 90 nm. PMMA nanoparticles were tested for toxicity in human leukemic cell strain K562 and they did not show any adverse effect on cell viability. Therefore, poly(methyl methacrylate) nanoparticles are suitable to encapsulate antitumor agents.

Interfacial properties rhamnolipids from an extract produced by a strain of Pseudomonas aeruginosa were analyzed in this study. The extract of rhamnolipid was characterized by surface tension in different conditions; interfacial tension with different hydrocarbons; critical micelle concentration under different pH and temperatures; particle size and emulsification capacity using laser light profiling. It was observed that the rhamnolipids extract are sensitive to variations in pH, thermostable and function as good emulsificant for emulsification of methyl methacrylate. The emulsion stability order in function of the oil phase was methyl methacrylate > emulsions of castor oil > emulsion n-heptane > emulsion toluene > emulsion hexadecane > octane emulsion. The data presented show that rhamnolipid extracts may be used to formulate stable emulsions of methyl methacrylate. This process can be used to do nano/microsphere of polymethyl methacrylate.

No abstract

Chronic inflammation is triggered by numerous diseases such as osteoarthritis, Crohn's disease and cancer. The control of the pro-inflammatory process can prevent, mitigate and/or inhibit the evolution of these diseases. Therefore, anti-inflammatory drugs have been studied as possible compounds to act in these diseases. This paper proposes a computational analysis of eugenol in relation to aspirin and diclofenac and analyzing the ADMET profile and interactions with COX-2 and 5-LOX enzymes, important enzymes in the signaling pathway of pro-inflammatory processes. Through the analysis of ADMET in silico, it was found that the pharmacokinetic results of eugenol are similar to NSAIDs, such as diclofenac and aspirin. Bioinformatics analysis using coupling tests showed that eugenol can bind to COX-2 and 5-LOX. These results corroborate with different findings in the literature that demonstrate anti-inflammatory activity with less gastric irritation, bleeding and ulcerogenic side effects of eugenol. The results of bioinformatics reinforce studies that try to propose eugenol as an anti-inflammatory compound that can act in the COX-2/5-LOX pathways, replacing some NSAIDs in different diseases.

No abstract